Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATOC PET/CT for NETs
NCT03136328Phase 3Completed
- Sponsor
- Montefiore Medical Center
- Start
- May 2016
- Primary completion
- Mar 2017
- Modality
- Peptides
01
Overview
Phase 3, open-label, single-arm trial of gallium Ga 68-edotreotide in neuroendocrine tumors (NETs), sponsored by Montefiore Medical Center. Primary endpoint: Sensitivity to Correctly Diagnose NET at 120 minutes. Started May 2016; status: completed.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03136328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136328.